Private equity and venture capital firms spend months analyzing market dynamics, competitive landscapes, and management teams before writing checks. They stress-test financial models, conduct extensive due diligence, and negotiate protective covenants. But many are underestimating one of the biggest threats to their portfolio returns: regulatory and narrative risk—policy decisions, enforcement shifts, and public backlash that can derail even the strongest business models overnight.
AI chipmaker Cerebras Systems filed for its highly anticipated IPO last September, expecting to raise $1 billion at an $8 billion valuation. The company burned through cash for months in regulatory limbo, its national security review frozen due to federal staffing bottlenecks. When Cerebras finally cleared the Committee on Foreign Investment in the United States (CFIUS) review in March 2025, the market had already moved on. But that’s the dirty secret of regulatory delays; they don’t just pause deals, they poison them.
